DE60006495D1 - Pharmazeutische kombination von antiviralen wirkstoffen - Google Patents

Pharmazeutische kombination von antiviralen wirkstoffen

Info

Publication number
DE60006495D1
DE60006495D1 DE60006495T DE60006495T DE60006495D1 DE 60006495 D1 DE60006495 D1 DE 60006495D1 DE 60006495 T DE60006495 T DE 60006495T DE 60006495 T DE60006495 T DE 60006495T DE 60006495 D1 DE60006495 D1 DE 60006495D1
Authority
DE
Germany
Prior art keywords
pharmaceutical combination
antiviral active
active substances
antiviral
nnrtis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60006495T
Other languages
English (en)
Other versions
DE60006495T2 (de
Inventor
Robert Rando
Zhengxian Gu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shire Canada Inc
Original Assignee
Shire BioChem Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shire BioChem Inc filed Critical Shire BioChem Inc
Publication of DE60006495D1 publication Critical patent/DE60006495D1/de
Application granted granted Critical
Publication of DE60006495T2 publication Critical patent/DE60006495T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DE60006495T 1999-03-01 2000-03-01 Pharmazeutische kombination von antiviralen wirkstoffen Expired - Fee Related DE60006495T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12248099P 1999-03-01 1999-03-01
US122480P 1999-03-01
PCT/CA2000/000212 WO2000051641A1 (en) 1999-03-01 2000-03-01 Pharmaceutical combination of antiviral agents

Publications (2)

Publication Number Publication Date
DE60006495D1 true DE60006495D1 (de) 2003-12-18
DE60006495T2 DE60006495T2 (de) 2004-04-15

Family

ID=22402949

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60006495T Expired - Fee Related DE60006495T2 (de) 1999-03-01 2000-03-01 Pharmazeutische kombination von antiviralen wirkstoffen

Country Status (9)

Country Link
US (2) US6511983B1 (de)
EP (1) EP1159005B1 (de)
JP (1) JP2002538171A (de)
AT (1) ATE253938T1 (de)
AU (1) AU771196B2 (de)
CA (1) CA2363982A1 (de)
DE (1) DE60006495T2 (de)
ES (1) ES2208281T3 (de)
WO (1) WO2000051641A1 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1501828A (zh) * 2000-12-15 2004-06-02 ������˹ҩƷ��˾ 用肌苷一磷酸脱氢酶抑制剂进行的dapd联合治疗
CA2383259A1 (en) 2002-04-23 2003-10-23 Celator Technologies Inc. Synergistic compositions
US7850990B2 (en) 2001-10-03 2010-12-14 Celator Pharmaceuticals, Inc. Compositions for delivery of drug combinations
JP4445262B2 (ja) 2001-10-09 2010-04-07 アムジェン インコーポレイテッド 抗炎症剤としてのイミダゾール誘導体
EP1448170A4 (de) * 2001-11-27 2010-05-12 Bristol Myers Squibb Co Efavirenz-tablettenformulierung mit einzigartigen biopharmazeutischen eigenschaften
WO2004087139A1 (en) * 2003-03-27 2004-10-14 Boehringer Ingelheim International Gmbh Antiviral combination of tipranavir and a further antiretroviral compound
FR2878747B1 (fr) * 2004-12-03 2007-03-30 Pierre Fabre Medicament Sa Utilisation d'acide(s) gras omega-3 pour le traitement de l'hypercholesterolemie causee par un traitement anti-retroviral chez les patients infectes par le vih
MX2010003542A (es) * 2007-10-02 2010-06-02 Univ Emory Potentes combinaciones de zidovudina y fármacos que se seleccionan para la mutacion k65r en la polimerasa de vih.

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4724232A (en) * 1985-03-16 1988-02-09 Burroughs Wellcome Co. Treatment of human viral infections
US5041449A (en) 1988-04-11 1991-08-20 Iaf Biochem International, Inc. 4-(nucleoside base)-substituted-1,3-dioxolanes useful for treatment of retroviral infections
US5270315A (en) * 1988-04-11 1993-12-14 Biochem Pharma Inc. 4-(purinyl bases)-substituted-1,3-dioxlanes
US5366972A (en) * 1989-04-20 1994-11-22 Boehringer Ingelheim Pharmaceuticals, Inc. 5,11-dihydro-6H-dipyrido(3,2-B:2',3'-E)(1,4)diazepines and their use in the prevention or treatment of HIV infection
US5276151A (en) 1990-02-01 1994-01-04 Emory University Method of synthesis of 1,3-dioxolane nucleosides
US5179104A (en) 1990-12-05 1993-01-12 University Of Georgia Research Foundation, Inc. Process for the preparation of enantiomerically pure β-D-(-)-dioxolane-nucleosides
US5925643A (en) 1990-12-05 1999-07-20 Emory University Enantiomerically pure β-D-dioxolane-nucleosides
US5444063A (en) * 1990-12-05 1995-08-22 Emory University Enantiomerically pure β-D-dioxolane nucleosides with selective anti-Hepatitis B virus activity
GB9200150D0 (en) * 1992-01-06 1992-02-26 Wellcome Found Therapeutic nucleosides
US5792773A (en) 1996-11-15 1998-08-11 Yale University L-β-dioxolane uridine analog administration for treating Epstein-Barr virus infection

Also Published As

Publication number Publication date
AU2899000A (en) 2000-09-21
US6887879B2 (en) 2005-05-03
EP1159005A1 (de) 2001-12-05
US6511983B1 (en) 2003-01-28
EP1159005B1 (de) 2003-11-12
ATE253938T1 (de) 2003-11-15
JP2002538171A (ja) 2002-11-12
DE60006495T2 (de) 2004-04-15
US20030045534A1 (en) 2003-03-06
AU771196B2 (en) 2004-03-18
WO2000051641A1 (en) 2000-09-08
ES2208281T3 (es) 2004-06-16
CA2363982A1 (en) 2000-09-08

Similar Documents

Publication Publication Date Title
BG100455A (en) Hiv protease inhibitors
BR0015605A (pt) Composição e uso
ATE450265T1 (de) Pharmazeutische mischung zur behandlung von krebs,die dioxolan nukleosidanalogen enthält
MD1224B2 (en) Application of nucleoside analogues with 1,3-oxathiolan for treatment of hepatitis B
DK1280813T3 (da) Antivirale pyrimidin-nukleosidanaloger
BR0113666A (pt) Inibidores da protease peptidomimética
AP1782A (en) Use of compounds ?-D or ?-L nucleoside for treating hepatitis C virus.
DK1265889T3 (da) Lægemidler imod virussygdomme
LU90839I2 (fr) Kaletra-combinaison de lopinavir et de ritonavir et ses d-riv-s pharmaceutiquement acceptables
BR0115447A (pt) Inibidores de tripeptìdeo de hepatite c
EA199901031A1 (ru) Производные бензимидазола
CY1110690T1 (el) Ενωσεις 4-οξοκινολινης και χρησιμοποιηση αυτων ως αναστολεις της ενσωματασης του hiv
ATE131730T1 (de) Nukleosidanalogen enthaltende antiviren- zubereitungen
ATE249219T1 (de) Antivirale verbindungen
MXPA03006224A (es) Inhibidores de cruzipaina y otras proteasas de cisteina.
EA200600227A1 (ru) Замещённые арилтиомочевины, применимые в качестве ингибиторов репликации вирусов
DE69518840T2 (de) N-(3-amino-2-hydroxybutyl)sulfonamid-derivate as hiv-protease-inhibitoren
DE60006495D1 (de) Pharmazeutische kombination von antiviralen wirkstoffen
TR200102024T2 (tr) Yeni tedavi.
ATE289813T1 (de) Typ v pde-hemmer zur behandlung von mukoviszidose
ATE348621T1 (de) Flüssige darreichungsformen oxazaphosphorinhaltiger pharmazeutischer produkte
FI951078A (fi) Retrovirusinfektion inhibitio
ATE301997T1 (de) Antivirale therapie
NO992228D0 (no) 1-(3-aminoindazol-5-yl)-3-fenylmetyl-syklisk urea egnet som HIV protease inhibitor
ATE270886T1 (de) Antivirale therapie

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: SHIRE CANADA INC., VILLE ST.-LAURENT, QUEBEC, CA

8339 Ceased/non-payment of the annual fee